Teva prices thrice-weekly Copaxone

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) set the wholesale acquisition cost (WAC) of a four-week supply of its thrice-weekly 40 mg dose of multiple sclerosis (MS) drug Copaxone glatiramer acetate at $4,641.24, which translates to an annual WAC of about $60,336. The price is about a 2% discount to Teva's marketed once-daily 20 mg dose of Copaxone. The company markets a 30-day supply of the once-daily dose at a WAC of $5,060.33, which translates to an annual WAC of about $61,567.

FDA approved the thrice-weekly dose late Tuesday. Teva said the new dose will be available to patients "within days" (see BioCentury Extra, Jan. 28). ...